Taiwan Showcases AI and Regenerative Medicine at BioJapan 2025

TAIPEI, October 6, 2025 — The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) has announced its leadership of a delegation consisting of 16 biotech industry partners from Taiwan to participate in BioJapan 2025, scheduled for October 8-10 in Yokohama. This event will serve as a significant platform for Taiwan to highlight its innovative capabilities in biotechnology and foster collaborative opportunities with Japanese companies.

Showcasing Taiwan’s Biotech Strengths

During BioJapan 2025, the Taiwan Pavilion will present Taiwan’s competitive edge in high-growth sectors, particularly in regenerative medicine, AI healthcare, precision health, and contract development and manufacturing organizations (CDMOs). The Taiwanese biotech ecosystem is characterized by a unique combination of expertise, innovation, and collaboration, which is expected to attract interest from industry stakeholders in Japan.

Recent successes underscore the increasing presence of Taiwanese companies in the Japanese market. In 2024, Japan’s CBC became an official distributor for Taiwan’s Taipei Medical University Hospital (TBMC), enhancing TBMC’s market opportunities in Japan. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in Japan, marking a significant achievement in international expansion.

Collaborative Developments and Future Prospects

This year has seen several strategic partnerships emerge between Taiwanese and Japanese biotech firms. Amaran Biotech established a collaboration with Nippon Fine Chemical to advance CDMO manufacturing technology services for nanoparticle-based drugs in both Taiwan and Japan. Furthermore, Taiwanese company AM Biotech recently had its high-purity targeted exosomes registered with the Japan Cosmetic Industry Association, expanding their applicability from cosmetics to regenerative medicine.

Another notable collaboration involves LumiSTAR, which was selected to participate in Takeda Pharmaceutical’s COCKPI-T® program aimed at enhancing drug discovery and development. Steminent is also making progress, having secured Foreign Manufacturer Accreditation from the Japanese government, with plans to achieve certification for its new regenerative medicine, Stemchymal®, by 2026.

As a testament to the strengthening ties between Taiwan and Japan, Creative Life Science is set to sign a memorandum of understanding with Japan’s Myoridge. This agreement aims to combine resources in cell culture and production channels, fostering new advancements in regenerative medicine.

The Taiwanese delegation will also visit Astellas Pharma, a prominent Japanese multinational pharmaceutical company, to tour its innovative SakuLab facility and explore potential collaborations in cell therapy and bioprocessing.

For further information on Taiwan’s participation in BioJapan 2025, please visit https://ccd.nat.gov.tw/biopharm.

Media inquiries can be directed to Janet Chung at [email protected].